Prime Medicine, Inc.
NASDAQ:PRMEBiotechnology
-$0.04 today
- Market cap
- $694.94M
- Beta
- 2.31
- P/E (TTM)
- -2.8
- EPS (TTM)
- -$1.12
Volume 4.62M
Average 2.47M
PRME Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Prime Medicine, Inc.NASDAQ: PRME
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin growth accelerates
Q1 FY2026 selling, general & admin of $17.41M rose 31.0% year over year, ahead of the +8.0% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 18.1% from the prior quarter. Over 3 fiscal years it compounded at +20.6% a year.
Context
- Selling, general & admin amounted to 1130.1% of revenue in FY2025, down 551.5 pp from a year earlier.
- Selling, general & admin increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 8 analysts of $66.57M (+27.2%) for the fiscal year ending Dec 2026, a step up from the +4.4% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $17.41M+18.1% QoQ
- Last fiscal yearDec 2025
- $52.35M+4.4% YoY
- LTMMar 2026
- $56.47M+8.0% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 52.35M USD
- Year-over-year change
- +4.4%
- 4-year CAGR
- +39.2%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 52.35M | +4.4% |
| FY2024 | 2024-12-31 | 50.16M | +15.6% |
| FY2023 | 2023-12-31 | 43.39M | +45.5% |
| FY2022 | 2022-12-31 | 29.82M | +114.2% |
| FY2021 | 2021-12-31 | 13.92M | — |
Selling, General & Admin vs competitors
How PRME compares with its peers on the latest reported figures
- PRME's LTM Mar 2026 selling, general & admin of $56.47M is the 4th highest of the 7 companies compared; the peer median is $57.83M.
- Its year-over-year change of +8.0% is the 4th highest of 7, against a peer median of +5.1%.
- Selling, general & admin amounts to 1399.8% of revenue for PRME, versus a peer median of 239.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $157.94M | +14.5% | +9.9% | 239.0% | |
| LTM Jun 2026 | $125.4M | +14.0% | +9.0% | 80.4% | |
| LTM Sep 2026 | $68.9M | -6.0% | -10.5% | 273.7% | |
| LTM Mar 2026 | $56.47M | +8.0% | +20.6% | 1399.8% | |
| LTM Mar 2026 | $46.76M | -29.2% | -11.0% | 120.9% | |
| LTM Mar 2026 | $36.25M | -1.5% | -0.1% | 323.5% | |
| LTM Mar 2026 | $20.62M | +11.6% | +2.3% | — | |
SCTXScribe Therapeutics Inc. | — | — | — | — | — |
| Peer median (excluding PRME) | $57.83M | +5.1% | +1.1% | 239.0% | |
Competitors are the stored peer set for PRME. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 2.98M | 4.63M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 7.32M |
| Gross Profit | 0 | 0 | 0 | 2.98M | (2.69M) |
| Gross Margin | — | — | — | 100.0% | -58.1% |
| Research & Development | 70.55M | 86.73M | 147.91M | 155.29M | 160.64M |
| Selling, General & Admin | 13.92M | 29.82M | 43.39M | 50.16M | 52.35M |
| Operating Expenses | 84.47M | 116.54M | 204.79M | 205.45M | 205.66M |
| Depreciation & Amortization | 568K | 2.22M | 4.65M | 6.13M | 5.38M |
| EBITDA | (165.29M) | (120.55M) | (186.64M) | (189.75M) | (195.76M) |
| EBITDA Margin | — | — | — | -6361.2% | -4226.2% |
| Operating Income | (84.47M) | (116.54M) | (204.79M) | (202.47M) | (208.35M) |
| Operating Margin | — | — | — | -6787.4% | -4498.1% |
| Interest Income | 0 | 0 | 0 | 3.52M | 4.15M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (81.38M) | (6.23M) | 6.38M | 6.59M | 7.21M |
| Income Before Tax | (165.85M) | (122.77M) | (198.41M) | (195.88M) | (201.14M) |
| Pre-Tax Margin | — | — | — | -6566.6% | -4342.4% |
| Income Tax Expense | (486K) | (948K) | (279K) | 0 | 0 |
| Net Income | (165.37M) | (121.82M) | (198.13M) | (195.88M) | (201.14M) |
| Net Margin | — | — | — | -6566.6% | -4342.4% |
| EPS (Basic) | (1.92) | (1.46) | (2.18) | (1.65) | (1.35) |
| EPS (Diluted) | (1.92) | (1.46) | (2.18) | (1.65) | (1.35) |
| Weighted Avg Shares | 95.73M | 97.21M | 90.97M | 118.6M | 148.76M |
| Weighted Avg Shares (Diluted) | 95.73M | 97.21M | 90.97M | 118.6M | 148.76M |
Prime Medicine, Inc.
NASDAQ:PRME
Intrinsic Alpha fair value
Locked
Current Price
$3.82
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.